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Introduction {#sec1}
============

Embryonic stem cells (ESCs) are derived from the inner cell mass of the blastocyst, which comprises pluripotent cells with the potential to differentiate into all cell types of the body ([@bib37]). This capacity enables ESCs a wide utilization in regenerative medicine and cell-based therapies. Therefore, a better understanding of the underlying mechanisms that modulate the differentiation of ESCs is essential for their clinical application in the future ([@bib6]).

Leukemia inhibitory factor (LIF) was found to be the key growth factor for the culture and maintenance of mouse ESCs (mESCs) *in vitro* ([@bib31], [@bib36]). LIF, a member of the interleukin-6 (IL-6) family of cytokines, binds to gp130/LIFR and results in the phosphorylation on tyrosine 705 residues of STAT3, a member of the STAT gene family identified in the interferon-induced regulatory pathways ([@bib8], [@bib12], [@bib13], [@bib29]). STAT3, first identified as a transcription factor (TF) for the IL-6 family of cytokines ([@bib1], [@bib41]), was subsequently found to be crucial for ESC pluripotency ([@bib2], [@bib4], [@bib26], [@bib27], [@bib40]). Conventional knockout of *Stat3* in mice results in embryonic lethality at embryonic day 6.5 (E6.5) ([@bib33]). By eliminating *Stat3* in the mouse oocytes and embryos we found that STAT3 has an essential role in inner cell mass lineage specification and maintenance, and in pluripotent stem cell identity through the OCT4-NANOG circuit ([@bib11]).

The c-Jun NH~2~-teminal kinase (JNK) belongs to the mitogen-activated protein (MAP) kinase family, which were initially identified as ultraviolet-responsive protein kinases that activated c-Jun by phosphorylating its NH~2~-terminal serine/threonine residues ([@bib10], [@bib17]). In response to growth factors, cytokines, and a number of environmental stresses, JNK is activated through a well-orchestrated cascade of MAP kinase activation ([@bib18], [@bib28]). In particular, mitogen-activated kinase kinase 4 and 7, isoforms of MAP2K, directly phosphorylate and activate JNK, which in turn leads to the phosphorylation of (TF) c-Jun and switching on of transcriptional regulation exclusively through formation of complex with other TFs, such as c-fos, in the activator protein-1 complex ([@bib9], [@bib35]). *JNK* is encoded by two ubiquitously expressed genes (*JNK1* and *JNK2*) and by a third gene (*JNK3*) that is selectively expressed in neurons. MAPKBP1 is a JNK binding protein and enhances the activation of JNK ([@bib19], [@bib21]). Recent studies indicated that JNK signaling is required for lineage-specific differentiation but not stem cell self-renewal. ESCs lacking *JNK1* show transcriptional deregulation of several lineage-commitment genes and fail to undergo neuronal differentiation, as do ESCs lacking JNK pathway scaffold proteins ([@bib39]). Studies also found that JNK binds to a large set of active promoters during the differentiation of stem cells and results in histone 3 phosphorylation on chromatin ([@bib34]). It is also reported that JNK regulates STAT3 activity via its Ser-727 phosphorylation, showing the crosstalk between STAT3 and JNK pathways ([@bib22]).

In this study, we further investigate how STAT3 integrate to the core regulatory circuit in ESC pluripotency and differentiation, and identify *Mettl8* as a downstream target of STAT3 in mESCs. We discover the role of METTL8 as a negative regulator of JNK signaling in stem cells. Our results provide insights into the crosstalk between STAT3 and JNK signaling during stem cell differentiation.

Results {#sec2}
=======

*Mettl8* Is a Direct Target of STAT3 in mESCs {#sec2.1}
---------------------------------------------

In this study, we further investigated how STAT3 crosstalk with other potential pathways in ESC pluripotency. Therefore, we screened for unknown factors that were regulated by STAT3 using ESCs treated with STAT3 inhibitors STA-21 and STATTIC ([@bib30], [@bib32]). Real-time PCR results obtained from screening for a library of 200 epigenetic candidates led us to identify *Mettl8* ([Figure 1](#fig1){ref-type="fig"}A). We found that the mRNA levels of *Mettl8* were downregulated after the two-inhibitor treatment ([Figure 1](#fig1){ref-type="fig"}B). Meanwhile, we checked *Mettl8*\'s protein level, which was also inhibited by STA-21 and STATTIC ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}).Figure 1*Mettl8* Is Transcriptionally Regulated by STAT3(A) Real-time PCR was performed to screen for changes when ESCs were treated with STA-21 and STATTIC for 1 hr.(B and C) E14 cells were treated with STA-21 and STATTIC for 6 hr and harvested. (B) Total RNAs were extracted and followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05. (C) Cell lysates were analyzed by western blot. The value of each band was calculated from three independent replicates and indicates the relative expression level after normalizing to the loading control actin.(D) Knockdown *Stat3* in E14 cells resulted in downregulation of *Mettl8* mRNA. Data are shown as the mean ± SD from three independent experiments.(E) Knockdown *Stat3* in E14 cells resulted in downregulation of METTL8 protein. The value of each band was calculated from three independent replicates and indicates the relative expression level after normalizing to the loading control actin.(F and G) E14 cells were transfected with Flag-vector or Flag-tagged STAT3 at increasing concentrations. (F) Total RNAs were extracted followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05. (G) Cell lysates were analyzed by western blot.(H) Bioinformatic analysis identifies three possible STAT3 binding sites on *Mettl8* gene labeled as P1, P2, and P3. Data are shown as the mean ± SD from three independent experiments.(I) Inducible Flag-METTL8 overexpression E14 cells were treated with or without doxycycline and culture in mediums with or without LIF for 6 days. Then colonies were stained for AP activity and cell lysates were analyzed by western blot. Scale bars, 0.5 cm.

To further confirm that *Mettl8* is a target of STAT3, we reduced *Stat3* transcript levels by employing *Stat3* small hairpin RNAs (shRNAs), and found that both *Mettl8* mRNA and protein levels in ESCs were reduced ([Figures 1](#fig1){ref-type="fig"}D and 1E). Next we validated this result with STAT3 overexpression in mESCs. When STAT3 was overexpressed, both *Mettl8* mRNA and protein levels were upregulated ([Figures 1](#fig1){ref-type="fig"}F and 1G). To examine whether STAT3 regulates *Mettl8* directly or indirectly, we used bioinformatics, and identified three possible STAT3 binding sites on *Mettl8* gene at −2,672, −83, and 1,020 bp (PROMO software). We then performed chromatin immunoprecipitation (ChIP) assay using the pY705-STAT3-specific antibody. We found the highest enrichment in a promoter region at −83 bp and a proximal enhancer at 1,020 bp of *Mettl8* gene ([Figure 1](#fig1){ref-type="fig"}H). These results show that STAT3 directly interacts with the regulatory regions of the *Mettl8.* Taken together, our evidence demonstrate STAT3 directly and positively regulates *Mettl8* expression in pluripotent cells.

To further figure out whether METTL8 exerts a key function downstream of STAT3 in ESCs, we created inducible METTL8 overexpression mESCs. After LIF withdrawal ESCs became differentiated, but METTL8 overexpression rescued this phenomenon and showed more ESC colonies stained positive for alkaline phosphatase (AP) ([Figure 1](#fig1){ref-type="fig"}I), suggesting that METTL8 mediates the role of STAT3 in pluripotent cells.

METTL8 Is Dispensable for the Maintenance of Pluripotency in mESCs {#sec2.2}
------------------------------------------------------------------

To examine the function of METTL8 in mESCs, we first induced mESCs to differentiation by retinoic acid (RA) treatment and found both mRNA and protein levels of *Mettl8* were reduced ([Figures 2](#fig2){ref-type="fig"}A and 2B). Similarly, during embryoid body (EB) formation, *Mettl8* was also significantly downregulated from day 6 onward and barely detectible at days 9--15 ([Figures 2](#fig2){ref-type="fig"}C and 2D). These data imply that expression of *Mettl8* is correlated with the pluripotent state of ESCs, thus we next evaluated the direct effect of METTL8 on ESC pluripotency. However, when *Mettl8* was knocked out, the morphology of ESCs showed no difference from the wild-type cells, which were positive in AP staining ([Figure 2](#fig2){ref-type="fig"}E). Moreover, mRNA and protein expressions of key pluripotent genes were not changed in *Mettl8* deficient or overexpressed mESCs ([Figures 2](#fig2){ref-type="fig"}F, 2G, 2H, and [S2](#mmc1){ref-type="supplementary-material"}A), and *Mettl8* overexpression or knockout had little impact on the clonogenicity of mESCs ([Figures 2](#fig2){ref-type="fig"}I and 2J). However, when cultured in sub-optimal conditions, self-renewal of *Mettl8*-null ESCs is weakened ([Figure 2](#fig2){ref-type="fig"}J). These results suggested METTL8 is dispensable for ESC pluripotency when *Mettl8*-null ESCs are cultivated in normal conditions but might play a role in ESC differentiation.Figure 2METTL8 Affects ESCs Differentiation Rather Than Pluripotency(A) Total RNAs were extracted from E14 cells treated with RA for 0 or 4 days, followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments. ^∗∗∗^p \< 0.001.(B) E14 cells were treated with RA for the indicated times and cell lysates were analyzed by western blot.(C and D) E14 cells were subjected to EB formation and cells were harvested at the indicated times. (C) Total RNAs were extracted followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments.^∗^p \< 0.05, ^∗∗∗^p \< 0.001. (D) Cell lysates were analyzed by western blot.(E) *Mettl8* KO and control E14 cells were stained for AP activity and pictures were taken. Scale bars, 100 μm.(F) Total RNAs were extracted from *Mettl8* KO and control E14 cells followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments.(G) Cell lysates of *Mettl8* KO and control E14 cells were analyzed by western blot.(H and I) E14 cells were transfected with Flag-vector or Flag-tagged METTL8 and (H) 48 hr later cell lysates were analyzed by western blot. (I) Colony-forming assays were performed and the number of AP-positive colonies was counted.(J) *Mettl8* KO and control cells were cultured under normal condition or LIF deprivation for 4 days. Then colony-forming assays were performed and the number of AP-positive colonies was counted. ^∗∗^p \< 0.01.(K) *Mettl8* KO and control E14 cells were subjected to EB formation for 7 days. EBs were trypsinized and re-plated into gelatin-coated dished. After 3 days culture in ESC medium, colonies were stained for AP activity and AP-positive colonies were counted. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05.(L) Inducible METTL8 overexpression E14 cells were treated with or without doxycycline and subjected to EB formation for 7 days, or treated with doxycycline for the first 3 days of EB formation. Then EBs were trypsinized and re-plated into gelatin-coated dishes. After 3 days culture in ESC medium, colonies were stained for AP activity and AP-positive colonies were counted. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01.

METTL8 Inhibits mESC Differentiation {#sec2.3}
------------------------------------

We next examined the function of METTL8 in differentiation assay of ESCs. Interestingly, after 10 days of EB formation, the numbers of AP-positive ESCs decreased in the *Mettl8* knockout (KO) group ([Figures 2](#fig2){ref-type="fig"}K and [S2](#mmc1){ref-type="supplementary-material"}B). Consistently, more ectopic expression of METTL8 led to higher AP-positive numbers from EBs ([Figure 2](#fig2){ref-type="fig"}L), which suggests that METTL8 impedes mESC differentiation. Then global gene transcriptome profiling was performed with whole-genome cDNA microarray to find out the genes with significant changes between *Mettl8* or scramble small interfering RNA (siRNA) mESCs ([Table S1](#mmc2){ref-type="supplementary-material"}). We found that 353 genes were upregulated (\>2-fold) and 89 transcripts were downregulated (\>2-fold) after *Mettl8* depletion. To define discreet functional clusters of common gene regulation, we performed a hierarchical clustering of our microarray data. This analysis yielded four discernable clusters of commonly regulated genes with two each associated with up- and downregulation ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Overall upregulated gene clusters were associated with developmental capacity. When we performed gene ontology we found that these upregulated genes are enriched for gene ontology terms such as developmental process and cellular differentiation. Particularly, we found some key upregulated lineage genes such as *Pax6, Gata6, T*, and *Hand1*, which have been reported to be upregulated during mESC differentiation ([Figure S2](#mmc1){ref-type="supplementary-material"}C). We also examined the global gene expression changes using RNA sequencing (RNA-seq) comparing the transcriptome from ESCs with either *Mettl8* or scramble siRNA. We found that 198 genes were downregulated (\>2-fold) and 1,353 transcripts were upregulated (\>2-fold) after *Mettl8* depletion ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Consistent with microarray data, we also found key upregulated developmental genes such as *Pax6, Gata6, T*, and *Hand1*, and then used real-time PCR to validate the increase in mRNA expression of these genes ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Taken together, these results suggested that METTL8 indeed inhibits ESC differentiation, possibly by suppressing expression of some key developmental genes.

METTL8 Functions in Somatic Reprogramming {#sec2.4}
-----------------------------------------

Given the role of METTL8 in the regulation of ESC differentiation, we sought to further explore its functions in induced pluripotent stem cells (iPSCs) and determine whether METTL8 also regulates somatic reprogramming. Firstly, using the well-established iPSC mouse model ([@bib5]), we found both mRNA and protein levels of *Mettl8* were increased during cellular reprogramming after inducing OSKM (OCT4, SOX2, KLF4, and MYC) in MEF cells ([Figures 3](#fig3){ref-type="fig"}A and 3B), indicating that METTL8 may facilitate reprogramming. To test this hypothesis, we crossed *Mettl8* KO with inducible OSKM strain to introduce *Mettl8* KO MEF cells along with OSKM induction. *Mettl8* deficiency indeed resulted in a decreased iPSC colony formation ([Figure 3](#fig3){ref-type="fig"}C). These *Mettl8* KO iPSC colonies shared a similar morphology with the wild-type ones ([Figure 3](#fig3){ref-type="fig"}D). In addition, RT-PCR analysis revealed that all of the randomly picked *Mettl8* KO MEF-derived colonies expressed endogenous ESC marker genes, including *Oct4, Sox2, Nanog, Rex1, Fbx15*, and *Esg1* ([Figure 3](#fig3){ref-type="fig"}E). Immunofluorescence analysis also showed that these colonies were positive for pluripotent markers OCT4 and SOX2 ([Figure 3](#fig3){ref-type="fig"}F). Together our results suggest that METTL8 play its role in somatic reprogramming.Figure 3METTL8 Functions in Somatic Reprogramming(A) Total RNA was extracted from OSKM-inducible MEF cells treated with doxycycline on days 0, 5, and 10, and iPSCs followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05.(B) Cell lysis from OSKM-inducible MEF cells treated with doxycycline on days 0, 5, and 10, and iPSCs and analyzed by western blot. The value of each band was calculated from three independent replicates and indicates the relative expression level after normalizing to the loading control actin.(C) Wild-type and *Mettl8* KO OSKM-inducible MEF cells were treated with doxycycline and induced for iPSCs. After 20 days, numbers of iPSC colonies were counted. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05.(D) Wild-type and *Mettl8* KO iPSCs were stained for AP activity and pictures were taken. Scale bars, 100 μm.(E) Total RNA from MEF cells, E14 cells, and the indicated *Mettl8* KO iPSC colonies were subjected to RT-PCR analysis for detection of expression of endogenous *Oct4, Sox2, Nanog, Rex1, Fbx15*, and *Esg1*. Actin was used as an internal control.(F) *Mettl8* KO iPSC colonies were subjected to immunofluorescence for analysis of endogenous OCT4 and SOX2 expression. Scale bars, 50 μm.

METTL8 Interacts with *Mapkbp1* mRNA {#sec2.5}
------------------------------------

As we discovered simultaneously that METTL8 interacts with mRNAs ([@bib38]), to further understand the mechanism of METTL8 in pluripotent cells, we sought to identify METTL8-interacting RNAs by photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) assay ([@bib16]) ([Figure 4](#fig4){ref-type="fig"}A). The subsequent analysis indeed revealed that mRNAs are potential METTL8 protein interacting partners, which account for a large proportion of the binding peaks ([Table S2](#mmc3){ref-type="supplementary-material"}). This result was matched with the subcellular distribution of METTL8 protein that it is mainly located at the cytoplasm where most mature mRNA resides ([Figure 4](#fig4){ref-type="fig"}B). To elucidate the mechanism by which METTL8 works through its mRNA partners, we chose *Mapkbp*1 mRNA from the candidates for detailed investigation, and RNA immunoprecipitation (RIP) assay was performed. We discovered that *Mapkbp1* mRNAs were enriched in Flag-tagged METTL8 expression sample, which confirmed METTL8 protein\'s ability to bind *Mapkbp1* mRNA ([Figure 4](#fig4){ref-type="fig"}C). The endogenous complex between METTL8 protein and *Mapkap1* mRNA was also detected by RIP assay using METTL8 antibody ([Figure 4](#fig4){ref-type="fig"}D). In addition, the interaction of METTL8 with *Mapkbp1* mRNA was further verified by affinity pull-down of endogenous *Mapkbp*1 mRNA using a biotinylated RNA antisense probe to *Mapkbp*1 mRNA ([Figure 4](#fig4){ref-type="fig"}E).Figure 4METTL8 Binds to *Mapkbp1* mRNA(A) Schematic illustration of PAR-CLIP assay.(B) E14 cells were harvested and subjected to cell fractionation. Each fraction was collected and analyzed by western blot.(C) HEK293T cells were transfected by the indicated plasmids. After 48 hr cells were harvested and subjected to RIP with flag antibody. Total RNAs were extracted followed by real-time PCR analysis. Actin was used as an internal control. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05.(D) E14 cells were harvested and subjected to RIP with METTL8 antibody or isotype-matched immunoglobulin G (IgG). Total RNAs were extracted and relative level of *Mapkbp1* mRNA was analyzed by quantitative real-time PCR. Actin was used as an internal control. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05.(E) E14 cells were harvested and cell lysates were then incubated with *in*-*vitro*-synthesized biotin-labeled sense or antisense *Mapkbp1* mRNA probes for biotin pull-down assay, followed by western blot analysis.

METTL8 Inhibits *Mapkbp1* mRNA Translation {#sec2.6}
------------------------------------------

To clarify the influence of METTL8 protein on its interacting partner, we next tested the expression level of *Mapkbp1* mRNA after knocking out *Mettl8* in ESCs. The results showed no significant change between *Mettl8* KO and control cells ([Figure 5](#fig5){ref-type="fig"}A). Similar results were obtained when METTL8 was overexpressed in HEK293T cells ([Figure 5](#fig5){ref-type="fig"}B), demonstrating that METTL8 does not affect mRNA levels of *Mapkbp1*. Thus, we then checked the protein level of *Mapkbp1*, and found a higher expression of MAPKBP1 protein in *Mettl8* KO cells ([Figures 5](#fig5){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}A). Based on this data, we speculated that METTL8 decreases the protein stability of MAPKBP1. However, when ESCs treated with cycloheximide (CHX) and protein synthesis was blocked, the degradation rate of MAPKBP1 protein showed no significant change between *Mettl8* KO and control cells ([Figure 5](#fig5){ref-type="fig"}D), indicating that protein stability of MAPKBP1 was not affected. Then we hypothesized that METTL8 may influence translation, and to directly test the possibility, *Mettl8* KO and control ESC lysates were subjected to polysome profiling by fractionation through sucrose gradients. The lightest components sedimented at the top (fractions 1 and 2), small (40S) and large (60S) ribosomal subunits and monosomes (80S) located in fractions 3 to 8, and larger polysomes in fractions 9 to 15 ([Figure 5](#fig5){ref-type="fig"}E). *Mettl8* KO did not change global polysome distribution profiles, indicating that it did not affect global translation ([Figure 5](#fig5){ref-type="fig"}E). After isolating RNA from each fraction, real-time PCR analysis indicated that *Mapkbp1* mRNA in *Mettl8* KO cells was abundant in fractions 12 to 15, while in control cells it was abundant in fractions 4 to 6 and 11 to 13 ([Figure 5](#fig5){ref-type="fig"}F). The result indicates that silencing *Mettl8* leads to *Mapkbp1* mRNA distribution shifting toward larger polysomes and thus promotes translation. As a negative control, actin mRNA did not show that shift ([Figure 5](#fig5){ref-type="fig"}F). Taken together METTL8 affects *Mapkbp1* expression through binding to *Mapkap1* mRNA and inhibiting its translation.Figure 5*Mettl8* Deficiency Enhances *Mapkbp1* mRNA Translation(A) Total RNAs were extracted from *Mettl8* KO and control E14 cells followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments.(B) HEK293T cells were transfected by indicated plasmids. After 48 hr total RNAs were extracted followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments.(C) Cell lysates of *Mettl8* KO and control E14 cells were analyzed by western blot. The value of each band was calculated from three independent replicates and indicates the relative expression level after normalizing to the loading control actin.(D) *Mettl8* KO and control E14 cells were treated with CHX for the indicated times and cell lysates were analyzed by western blot. The value of each band was calculated from three independent replicates and indicates the relative expression level after normalizing to the loading control actin.(E) Global polysome profiles of *Mettl8* KO and control E14 cells were analyzed by sucrose gradient sedimentation.(F) Each fraction from sucrose gradient sedimentation was collected and total RNA was extracted. Levels of *Mapkbp1* mRNA were analyzed by quantitative real-time PCR.

METTL8 Inhibits JNK Signaling in mESCs {#sec2.7}
--------------------------------------

To further understand the consequences of the interaction between METTL8 and *Mapkbp1* mRNA, we next investigated the role of MAPKBP1 in ESCs. We induced differentiation of ESCs by RA treatment and found mRNA levels of *Mapkbp1* were not changed during the process ([Figure 6](#fig6){ref-type="fig"}A). This result was expected as we postulate that mRNA expression of *Mapkbp1* is not affected by METTL8. However, an increase of MAPKBP1 protein level was observed after RA treatment, accompanying the emergence of phosphorylated JNK, which was not detectable in that pluripotent state ([Figures 6](#fig6){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). Moreover, the expression levels of both MAPKBP1 and phosphorylated JNK were higher in *Mettl8* KO cells than control cells ([Figures 6](#fig6){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). These results suggest that *Mettl8* KO enhances JNK signaling during differentiation. To further confirm the hypothesis, we employed another model of ESC differentiation, EB formation, and also found an enhanced JNK signal in *Mettl8* KO EBs ([Figure 6](#fig6){ref-type="fig"}C). By contrast, although level of phosphorylated JNK protein was quite low in MEFs, during somatic reprogramming MAPKBP1 and phosphorylation of JNK showed a decreasing tendency and still appeared at higher levels in *Mettl8* KO cells ([Figure 6](#fig6){ref-type="fig"}D). Finally we performed the JNK assay and confirmed that the enzyme activity of JNK was indeed enhanced in *Mettl8*-deficient cells ([Figure 6](#fig6){ref-type="fig"}E). Taken together, METTL8 inhibits JNK signaling through MAPKBP1 in mESCs.Figure 6METTL8 Inhibits JNK Signaling in ESCs(A) Total RNAs were extracted from E14 cells treated with RA for 0 or 4 days, followed by real-time PCR analysis. Data are shown as the mean ± SD from three independent experiments.(B) *Mettl8* KO and control E14 cells were treated with RA for the indicated times and cell lysates were analyzed by western blot. The value of each band was calculated from three independent replicates and indicates the relative expression level after normalizing to the loading control actin.(C) *Mettl8* KO and control E14 cells were subjected to EB formation and 21 days later cell lysates were analyzed by western blot. The value of each band was calculated from three independent replicates and indicates the relative expression level after normalizing to the loading control actin.(D) *Mettl8* KO and control MEF cells were induced to iPSCs and collected at indicated times. Cell lysates were analyzed by western blot.(E) *Mettl8* KO and control E14 cells were treated with RA for 0 or 4 days were harvested and cell lysates were subjected to JNK assay, followed by western blot analysis.

The METTL8-MAPKBP1-JNK Pathway Suppresses ESC Differentiation {#sec2.8}
-------------------------------------------------------------

To further validate that METTL8 regulates the JNK pathway during differentiation, we next performed *in vitro* differentiation assays in ESCs. According to a previous study, JNK proteins are mostly enriched for regulating genes involved in nervous and cardiovascular system development ([@bib34]). Therefore we next subjected mESCs to neural and cardiac differentiation *in vitro*. When *Mettl8* was silenced, neuronal differentiation was enhanced, which, however, showed no significant change in *Mettl8* and *Mapkbp1* double KO (DKO) cells ([Figures 7](#fig7){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A). Similarly, cardiac differentiation of *Mettl8* KO cells followed the same pattern in *Mettl8* and *Mapkbp1* DKO cells ([Figures 7](#fig7){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B). Moreover, we also examined markers of other germline layers, some of which were also upregulated in *Mettl8* KO cells and rescued in *Mettl8* and *Mapkbp1* DKO cells ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). These results indicate that MAPKBP1 mediates the function of METTL8 during differentiation. Meanwhile we performed the same assays in *Mettl8* KO cells treated with JNK inhibitor SP600125, and the number of cells with *Nestin* and *Gata4* expression was consistently reduced compared with those without treatment ([Figures 7](#fig7){ref-type="fig"}C, 7D, [S4](#mmc1){ref-type="supplementary-material"}E, and S4F). The expression of other lineage markers was also lower in SP600125-treated *Mettl8* KO cells ([Figures S4](#mmc1){ref-type="supplementary-material"}G and S4H), indicating that METTL8-MAPKBP1 regulates ESC differentiation by the JNK pathway.Figure 7The METTL8-JNK Pathway in ESC Differentiation(A) *Mettl8* KO, *Mapkbp1* KO, *Mettl8*, and *Mapkbp1* DKO, and control E14 cells, were subjected to neuron progenitor cells differentiation. Cells were stained for expression of Nestin and positive cells were counted by cytometer. Data are shown as the mean ± SD from three independent experiments. ^∗∗∗^p \< 0.001. Scale bars, 100 μm.(B) *Mettl8* KO, *Mapkbp1* KO, *Mettl8*, and *Mapkbp1* DKO, and control E14 cells, were subjected to cardiac differentiation. Cells were stained for expression of Gata4 and positive cells were counted under fluorescence microscopy. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05. Scale bars, 100 μm.(C) *Mettl8* KO and control E14 cells were treated with or without SP600125 and subjected to neuron progenitor cells differentiation. Cells were stained for expression of Nestin and positive cells were counted by cytometer. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05. Scale bars, 100 μm.(D) *Mettl8* KO and control E14 cells were treated with or without SP600125 and subjected to cardiac differentiation. Cells were stained for expression of Gata4 and positive cells were counted under fluorescence microscopy. Data are shown as the mean ± SD from three independent experiments. ^∗^p \< 0.05. Scale bars, 100 μm.

Taken together, as depicted in [Figure S5](#mmc1){ref-type="supplementary-material"}A, our results unravel a pathway whereby STAT3 regulates mESC differentiation by transcriptionally activating *Mettl8*, which, in turn, inhibits JNK signaling through interaction with a key JNK modulator, *Mapkbp1* mRNA and attenuating its translation.

Discussion {#sec3}
==========

In this study, we identified *Mettl8* as a transcriptional target of STAT3 that mediates STAT3's functions in mESCs. According to previous studies, STAT3 responds to external cytokine LIF and then transcribes critical pluripotent factors in the nucleus, such as *Oct4* and *Nanog*. Nevertheless, it remains undefined if STAT 3 is able to regulate stem cell pluripotency or differentiation by other mechanisms. We report here that METTL8 mediates a role of STAT3 during ESC differentiation. Our results indicate that STAT3, besides modulating *Oct4* and *Nanog* expression, plays diverse roles in maintenance of ESC identity.

We found that METTL8 impedes differentiation of mESCs rather than pluripotency. Through RNA-seq and microarray analysis, it is discovered that lineage markers increased in *Mettl8*-deficient ESCs, while pluripotency markers showed no change. However, we think those elevated lineage genes are not a strong enough driving force for ESC differentiation. As a result, *Mettl8* KO cells maintain a pluripotent state. Nevertheless, once those *Mettl8*-deficient cells were deprived of pluripotent conditions they would be more vulnerable to differentiate. However, different to embryo lethality caused by *Stat3* deficiency, no abnormal phenotype was observed in *Mettl8* KO mice. So it needs further investigation if there is redundancy between METTL family members. One of the METTL family genes, *Mettl3*, is also reported to bind mRNA transcripts, and inhibits mRNA stability ([@bib14]).

We also used an affinity purification approach and subsequent mass spectrometry analysis to explore the interacting proteins with METTL8, and found a number of RNA binding proteins in the candidates list ([Table S3](#mmc4){ref-type="supplementary-material"}). This result suggests that the binding between METTL8 and *Mapkbp1* mRNA may be not direct, and that some RNA binding proteins may mediate the interaction, which needs further investigation. In addition, mRNA of *Gata6*, which is a lineage marker, was also proved to bind to METTL8 by subsequent experiments (data not shown). Coincidently *Gata6* mRNA also showed an upregulation in *Mettl8* knockdown cells in both microarray and RNA-seq analysis, which suggests that METTL8 may affect differentiation through alternative factors and mechanisms.

It is reported that METTL8 causes 3-methylcytidine (m3C) modification on human mRNAs ([@bib38]). METTL8 contains a conserved methytransferase domain and is predicted to have methytransferase activity. Consistently, from the PAR-CLIP data in our study, most candidate METTL8 binding partners are mRNAs. We should further investigate if METTL8 modifies m3C on *Mapkbp1* mRNA and then causes translation inhibition. In addition, other METTL family proteins also reported to modify mRNAs. For example, METTL3 and METTL14 catalyze m(6)A RNA methylation ([@bib23]), which is critical for glioblastoma stem cell self-renewal ([@bib7]).

MAPKBP1 enhances JNK signaling activated by mitogen-activated protein kinase kinase 1 (MEK1) and transforming growth factor β-activated kinase 1 ([@bib19]). Given that extracellular signal-regulated kinase (ERK) signaling is a major driving force for mESC differentiation and that MEK 1 also activates ERK signaling, the crosstalk between JNK and ERK signaling is worth being further studied. Moreover, studies showed that JNK signaling is required for lineage-specific differentiation but not stem cell self-renewal ([@bib39]), which is consistent with our finding that METTL8 affects differentiation but not the pluripotent state. It is reported that JNK signaling can induce STAT3-Ser727 phosphorylation, which is important for the transactivation potency of STAT3 ([@bib22]). Here, we also found that, when the STAT3 pathway was inhibited, JNK phosphorylation showed a higher level. However, this phenotype became subtle in *Mettl8* KO cells, indicating that STAT3 has a feedback on JNK signaling in mESCs mediated by METTL8 ([Figure S5](#mmc1){ref-type="supplementary-material"}B).

Taken together, our results identified a signaling axis STAT3-METTL8-MAPKBP1-JNK that is important for mESC differentiation and further broadens the landscape of regulatory networks in mESCs.

Experimental Procedures {#sec4}
=======================

Cell Culture and RNA Interference {#sec4.1}
---------------------------------

mESCs were maintained in Glasgow minimum essential medium supplemented with 15% fetal bovine serum (FBS), 2 mM L-glutamine, 100 mM non-essential amino acids, 0.1 mM β-mercaptoethanol, 1 mM sodium pyruvate (Invitrogen) and 1,000 U/mL LIF (Millipore) on gelatin-coated plates. MEF and HEK293T cells were cultured in DMEM supplemented with 10% FBS (Invitrogen).

*Stat3* shRNA was cloned into pLVX vector with target sequence of GATCCCCGGGCCATCCTAAGCACAAAttcaagagaTTTGTGCTTAGGATGGCCCTTTTTA and co-transfected into HEK293T cells with pVSVG and gag/pol plasmids. Twelve hours after transfection, cells were cultured with DMEM medium containing 20% FBS for an additional 24 hr. The culture medium containing lentivirus particles was filtered through a 0.45-μm filter (Millipore) and incubated with mESCs supplemented with 4 mg/mL polybrene (Sigma) for 12 hr, followed by selection with 5 mg/mL puromycin for another 24 hr.

AP Staining {#sec4.2}
-----------

AP staining was detected using the Alkaline Phosphatase Detection Kit (Millipore) according to the manufacturer\'s recommendations.

RNA Extraction, Reverse Transcription, and Quantitative Real-Time PCR {#sec4.3}
---------------------------------------------------------------------

RNA was extracted using TRIzol reagent (Invitrogen) and treated with DNaseI (Amicon). cDNA synthesis was performed with 1 μg of total RNA and the Superscript III kit (Invitrogen) according to the manufacturer\'s instructions. Endogenous mRNA levels were measured by real-time PCR analysis based on SYBR Green detection with an ABI real-time PCR machine. The sequence of real-time PCR primers is provided in [Table S4](#mmc1){ref-type="supplementary-material"}. Samples were assayed in duplicate and normalized to endogenous *actin.*

Microarray Analysis {#sec4.4}
-------------------

mESCs were transfected with siRNA targeted against either *Mettl8* or a scrambled siRNA control. After 72 hr growth in selection media, total RNA was isolated by an RNAeasy purification kit (QIAGEN). Microarray analysis was performed using an Agilent whole-mouse gene expression microarray according to the manufacturer\'s instructions. Duplicate samples were used to compare transcript expression differences between *Mettl8*-siRNA and scrambled-siRNA ESCs.

Protein Extraction and Western Blot {#sec4.5}
-----------------------------------

Protein extracts were obtained using cell lysis buffer (20 mM HEPES, 400 nM NaCl, 0.5% NP-40, 10% glycerol, 1 mM DTT) with protease inhibitor (Roche) and phosphatase inhibitor. Proteins were separated by SDS-PAGE, transferred to polyvinylidene fluoride membrane (Bio-Rad), and probed with specific primary antibody and appropriate HRP-conjugated secondary antibody. Signals were detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce). The following antibodies were used for western blot: α-STAT3 (1:1,000, Santa Cruz, sc-482), p-STAT3Y705 (1:1,000, Cell Signaling Technology, no. 9131), METTL8 polyclonal (1:2,000, produced by our lab), METTL8 monoclonal (1:1,000, produced by our lab), α-tubulin (1:2,500, Santa Cruz, sc-53646), β-actin (1:2,500, Santa Cruz, sc-8432), SOCS3 (1:1,000, Cell Signaling, no. 2923), OCT4 (1:1,000, Cell Signaling, no. 2840), SOX2 (1:200, Santa Cruz, sc-365964), MAPKBP1 (1:200, Santa Cruz, sc-514754), and Flag (1:1,000, Sigma, F1804).

ChIP {#sec4.6}
----

ChIP assays with mESCs were carried out as described previously ([@bib24]). In brief, cells were crosslinked with 1% formaldehyde for 10 min at room temperature and formaldehyde was neutralized by addition of 0.2 M glycine. Chromatin extracts containing DNA fragments with an average size of 500 bp were immunoprecipitated using α-pY705-STAT3 antibody. For all ChIP experiments, quantitative real-time PCR analyses were performed using SYBR-Green Master Mix.

RIP {#sec4.7}
---

RIP was performed as described previously ([@bib25]). In brief, 1--3 × 10^7^ cells were lysed in hypotonic buffer supplemented with RNase A inhibitor and DNase I before centrifugation. Cell lysates were precleared with protein A/G beads (Pierce) before they were incubated with protein A/G beads coated with the indicated antibodies at 4°C for 3 hr. After extensive washing, the bead-bound immunocomplexes were eluted using elution buffer (50 mM Tris \[pH 8.0\], 1% SDS, and 10 mM EDTA) at 65°C for 10 min. To isolate protein-associated RNAs from the eluted immunocomplexes, samples were treated with proteinase K, and RNAs were extracted by phenol/chloroform. Purified RNAs were then subjected to real-time PCR analysis.

Biotin Pull-Down Assay {#sec4.8}
----------------------

All processes were performed in the RNase-free conditions. For antisense oligomer affinity pull-down assay, sense or antisense biotin-labeled DNA oligomers corresponding to *Mapkbp1* mRNA (3 mg) were incubated with lysates from 2 to 3 × 10^7^ × 10^14^ cells. One hour after incubation, streptavidin-coupled Dynabeads (Invitrogen) were added to isolate the RNA-protein complex. For *in vitro* RNA pull-down assay, 3 mg *in-vitro*-synthesized biotin-labeled *Mapkbp1* mRNA was incubated with purified flag or flag-METTL8 protein for 3 hr. Streptavidin-coupled Dynabeads (Invitrogen) were then added to the reaction mix to isolate the RNA-protein complex.

Polysome Analysis {#sec4.9}
-----------------

E14 cells were preincubated with CHX (100 μg/mL, Sigma) for 15 min, and cytoplasmic lysates were prepared and fractionated by ultracentrifugation through 15%--50% linear sucrose gradients; 15 fractions were collected, and RNA extracted from each fraction was used for quantitative real-time PCR analysis.

CRISPR KO in E14 Cells {#sec4.10}
----------------------

E14 cells were transfected with pX459 plasmids containing gRNAs for *Mettl8* or *Mapkbp1*. Forty-eight hours later cells were treated with puromycin (5 μg/mL) for 48 hr. Then the live cells were collected, and each single cell was re-plated into 96-well plates and cultured. The knockout efficiency was confirmed by western blot.

Colony-Forming Assay {#sec4.11}
--------------------

Colony-forming assay was performed as described previously ([@bib15]). In brief, ESCs were trypsinized to obtain a single-cell suspension, and 600 cells were plated per 10-cm^2^ well. After 6 days, colonies were stained for AP activity and divided into two categories: differentiated and undifferentiated.

JNK Assay {#sec4.12}
---------

Cell lysates were incubated with c-Jun-conjugated beads and JNK activity was analyzed using a JNK activity assay kit (New England Bio Labs) according to manufacturer\'s instructions.

Neuron Progenitor Cell Differentiation {#sec4.13}
--------------------------------------

Neuron progenitor cell differentiation assay was performed as described previously ([@bib20]). To produce EBs, 200 × 10^14^ cells were cultured in hanging drops for 3 days. Ten EBs were plated on gelatin-coated dishes in knockout DMEM containing epidermal growth factor, basic fibroblast growth factor, and L-ascorbic acid. Eight to 24 hr later, the medium was replaced by proliferation medium: DMEM/F12 supplemented with 10% FBS, 2 mM L-glutamine, 20 nM progesterone, 100 mM putrescine, 25 mg/mL insulin, 50 mg/mL transferrin, and 30 nM sodium selenite.

Cardiac Differentiation {#sec4.14}
-----------------------

Cardiac differentiation assay was performed as described previously ([@bib3]). E14 cells were culture in hanging drops with differentiation media (DMEM supplemented with 10% FBS, L-glutamine, non-essential amino acids, sodium pyruvate, penicillin-streptomycin, β-mercaptoethanol, and ascorbic acid) (50 mg/mL), and diluted to 1,000 cells per 25 μL for 3 days. At day 4, EBs were transferred into gelatin-coated dishes, and the beating cardiomyocytes could be observed as early as day 8.

Induced Pluripotent Stem Cells {#sec4.15}
------------------------------

Animals were maintained in a certified facility, and all protocols were approved by IACUC of National University of Singapore. All procedures related to animals were performed in accordance with guidelines of AAALAC. iPSCs were induced as described previously ([@bib5]). MEF cells were isolated from E13.5 embryos of *Gt(ROSA)26Sor*^*tm1(rtTA∗M2)Jae*^ *Col1a1*^*tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae*^/J mice. Cells were treated with doxycycline and 20 days later iPSC colonies were counted.
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